

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Grand Pharmaceutical Group Limited**  
**遠大醫藥集團有限公司\***  
*(Incorporated in Bermuda with limited liability)*  
**(Stock Code: 00512)**

**VOLUNTARY ANNOUNCEMENT**

**THE NEW MRA DRUG OF THE GROUP EPLERENONE TABLETS  
WAS GRANTED DRUG REGISTRATION CERTIFICATE**

This announcement is made by the board of directors (the “**Board**”) of Grand Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Board is pleased to announce that Eplerenone Tablets, a new selective mineralocorticoid receptor antagonist (“**MRA**”) that cooperated by the Group and Nanjing Cavendish Bio-engineering Technology Co., Ltd. (“**Nanjing Cavendish**”), has been granted drug registration certificate by the National Medical Products Administration of the People’s Republic of China recently. As an exclusive product that been commercialized in China, Eplerenone Tablets’ successful approval for commercialization fills the gap in domestic second-generation MRA drugs.

Nanjing Cavendish was established in November 2006. It is a high-tech enterprise engages in the development of first generic drug of innovative drugs. Its products cover anti-tumor, leukemia, anti-anaerobic infection, anti-virus, hypertension, heart failure, diabetes and other disease treatment fields. The successful commercialization of Eplerenone Tablets is expected to promote further in-depth cooperation between the Group and Nanjing Cavendish in other product areas.

Eplerenone is a new MRA drug. It can block heart disease and vascular damage caused by excessive activation of mineralocorticoid receptor (“**MR**”) by binding to the MR. “The Guidelines for Prevention and Treatment of Hypertension in China (2018 Revision)” (《中國高血壓防治指南(2018年修訂版)》), “The Guidelines for Diagnosis and Treatment of Heart Failure in China” (《中國心力衰竭診斷和治療指南》) and “The Multidisciplinary Expert Consensus for Clinical Application of Mineralocorticoid Receptor Antagonists in China (2022)” (《鹽皮質激素受體拮抗劑臨床應用多學科中國專家共識(2022)》) recommends the clinical use of MRA drugs in the treatment of cardiovascular diseases such as heart failure and

hypertension. At present, MRA drugs that commonly used in clinical practice are mainly Spironolactone and Eplerenone. As a first-generation MRA drug, Spironolactone often has side effects such as gynecomastia, female amenorrhea, and postmenopausal bleeding due to its low selectivity for MR. In contrast, Eplerenone has higher MR selectivity and lower affinity for androgen receptor and progesterone receptor, so it has less side effects and is a safe and effective new generation of MRA drug.

“The Annual Report on Cardiovascular Health and Diseases in China (2021)” shows that there are about 245 million adults with hypertension in China and the prevalence of hypertension among residents over 18 years old is about 27.9%, but the treatment rate and control rate are only about 45.8% and 16.8%, respectively; while the prevalence of heart failure in Chinese residents over 35 years old is about 1.3%, of which heart failure with low ejection fraction accounts for approximately 40.2%. At present, Spironolactone is the only MRA drug in clinical practice in China. The commercialization of the Group’s Eplerenone Tablets will not only bring new treatment options for patients with hypertension and heart failure, but also better improve the quality of patients’ life.

The Group always puts focus on the R&D of innovative products and advanced technologies. Adhering to a patient-centered and innovation-driven approach, the Group will continue to increase its investment in world-class innovative products and advanced technologies to meet unmet clinical needs and enrich its product pipeline and improve supply chain. The Group adopts the strategy of “global expansion and dual-cycle operation”, forming a new pattern of domestic and international cycles that synergize with each other. In this way, the Group can make full use of its industrial advantages and R&D capabilities, to accelerate the commercialization process for innovative products and provide patients with more advanced and diverse treatment options globally.

**Warning:**

**The production, sales and corresponding profit of aforementioned product is subject to various factors such as market changes with uncertainty. Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

*Note: The English transliteration of the Chinese name(s) in this announcement is included for information purpose only, and should not be regarded as the official English name(s) of such Chinese name(s).*

By order of the Board  
**Grand Pharmaceutical Group Limited**  
Chairman  
**Dr. Tang Weikun**

Hong Kong, 3 August 2023

*As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Mr. Zhou Chao, Dr. Shi Lin and Mr. Yang Guang, and three independent nonexecutive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.*

*\* For identification purpose only*